Supporting an early role for TrpA1 activation during the onset of sensory symptoms during CIPN, a single administration of members the platinum and proteasome inhibitor classes of anti-cancer drugs into mice results in mechanical and cold allodynia within 12 hours of administration that is reduced in TRPA1 mutants or by blocking studies with the HC-030031 TrpA1 antagonist [42,43]. Here, TRPA1 is linked to cancer.